Latest Depression News

Zimplats' December quarter report reveals a decline in mined and milled volumes alongside increased cash costs per 6E ounce, even as key expansion projects advance steadily.

Actinogen Medical accelerates recruitment in its pivotal XanaMIA Alzheimer's trial while securing a strong cash position of $22.9 million, underpinning its late-stage development and commercial readiness.

TrivarX has secured positive feedback from the FDA on its pivotal trial design for MEB-001, an AI-driven algorithm targeting major depressive episode screening via sleep study data. The company is advancing site collaborations to launch a large-scale US trial.

Emyria Limited announces key leadership shifts with Greg Hutchinson stepping up as Executive Chairman and Dr. Michael Winlo transitioning to Chief Scientific Officer, aiming to scale innovative mental health therapies amid growing demand.

OD6 Metals has completed the acquisition of the historic Gulf Creek Copper Project in New South Wales, positioning itself to unlock significant copper potential using modern exploration techniques.

Eumundi Group has issued a second supplementary target's statement endorsing SEQ Hospitality Group's takeover offer, maintaining the recommendation to accept in the absence of a superior proposal and reaffirming the offer's fairness.